首页 | 本学科首页   官方微博 | 高级检索  
     


Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors
Authors:Das Debasis  Hong Jian  Chen Shu-Hui  Wang Guangyi  Beigelman Leonid  Seiwert Scott D  Buckman Brad O
Affiliation:Division of Discovery Chemistry Service, WuXi AppTec Co. Ltd, Waigaoqiao Free Trade Zone, Shanghai 200131, PR China. debasis_das@wuxiapptec.com
Abstract:Hepatitis C virus (HCV) is a major health burden, with an estimated 170 million chronically infected individuals worldwide, and a leading cause of liver transplantation. Patients are at increased risk of developing liver cirrhosis, hepatocellular carcinoma and even liver failure. In the past two decades, several approaches have been adopted to inhibit non-structural viral proteins. The RNA-dependent RNA polymerase (NS5B) of HCV is one of the attractive validated targets for development of new drugs to block HCV infection. In this review, we report the recent progress made towards identifying and developing benzothiadiazines as HCV NS5B polymerase inhibitors. The substituted benzothiadiazine class was identified by HTS in 2002 as an NS5B inhibitor. Further optimization and modification of the core has improved the potency and pharmacokinetic properties of substituted benzothiadiazines. Research on palm site-binding benzothiadiazine analogs and related derivatives and analogs is discussed in this article.
Keywords:
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号